| Description: |
PD 123319 is shown to discriminate between two subclasses of AII receptors in many different tissues. 125I-AII specifically labeled two classes of binding sites For AII in a membrane preparation of bovine adrenal glomerulosa cells. The first class (DuP-753 sensitive) represents approximately 85% of the total binding sites For AII and possesses a high affinity (IC50 of 92.9 nM) For DuP-753. PD-123319 does not have any effect on 125I-AII binding to this site. The second class of binding sites is more sensitive to PD-123319, with an IC50 of 6.9 nM, and has a much lower affinity For DuP-753 (IC50 around 10 microM). PD 123319 has no effect on cerebral blood flow autoregulation. Acute AT2-receptor blockade does not influence CBF autoregulation. Intravenous administration of PD 123319 to conscious hypertensive rats elicites an immediate dose-dependent increase in MAP that is sustained For approximately 7.4 min with 3 mg/kg PD 123319.For the detailed information of PD 123319, the solubility of PD 123319 in water, the solubility of PD 123319 in DMSO, the solubility of PD 123319 in PBS buffer, the animal experiment (test) of PD 123319, the cell expriment (test) of PD 123319, the in vivo, in vitro and clinical trial test of PD 123319, the EC50, IC50,and Affinity of PD 123319, Please contact DC Chemicals. |
